Specialty pharmacies reduce administrative burden and total cost of care as advanced therapies move to community sites, Fran ...

Pirtobrutinib plus venetoclax-rituximab reduced progression/death risk versus venetoclax-rituximab alone in R/R CLL/SLL, with higher undetectable MRD rates at 10–6. Head-to-head FLT3 inhibition in ...

Late-breaking phase 3 SENTRY data show selinexor plus ruxolitinib improves spleen volume, survival, and disease markers in myelofibrosis. Harrison, the study’s lead investigator, explained that while ...

For Europe to remain an attractive site for phase 3 research, he argued, regulatory predictability is paramount. El-Galaly ...

In 'Beyond the SALT Score: Evaluating Alopecia Areata More Holistically,' the expert dermatologist examined the following ...

Adhering to the current guideline standard for intraoperative nodal assessment in resected non–small cell lung cancer (NSCLC) ...

Arash Mostaghimi highlighted the scientific journey that led to Janus kinase (JAK) inhibitors becoming a treatment avenue for ...

Shannon L. Maude, MD, PhD, highlighted promising long-term disease-free survival and MRD negativity with tisagenleucel in ...

Evidence-Based Diabetes Management | Journals | The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

To mitigate this risk, the Chaparro recommends pairing pharmacologic therapy with light resistance or weight training and ...

Experts explain how longer-lasting anti-VEGF injections reduce treatment burden and improve real-world vision outcomes in AMD ...

In the final episode, 'From Specialist Roles to Unmet Needs: Advancing Alopecia Areata Care,' the panelists explored the ...